Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: A series of 17 cases


SİPAHİ O. R. , BARDAK S., Turhan T. , ARDA B. , PULLUKÇU H. , RUKSEN M., et al.

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, cilt.43, ss.757-764, 2011 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 43 Konu: 10
  • Basım Tarihi: 2011
  • Doi Numarası: 10.3109/00365548.2011.585177
  • Dergi Adı: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
  • Sayfa Sayısı: ss.757-764

Özet

Background: Linezolid is a bacteriostatic antibiotic with good cerebrospinal fluid penetration. The aim of this study was to evaluate the efficacy of linezolid in methicillin-resistant staphylococcal (methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant coagulase-negative Staphylococcus (MRCoNS)) meningitis. Methods: We extracted data and outcomes for all adult patients (age > 18 y) with culture-proven MRSA or MRCoNS meningitis treated with linezolid between January 2006 and September 2010 in our hospital. Demographic, clinical, and laboratory data and predisposing factors, as well as information on response to treatment and outcome were obtained by regular visits. Results: A total of 17 cases (9 MRCoNS, 7 MRSA, and 1 MRCoNS and MRSA mixed) fulfilled the inclusion criteria. All patients had hospital-acquired meningitis and had undergone neurosurgery. Cumulative microbiological success on day 5 was 88%. There was 1 staphylococcal meningitis-related death. There were no severe adverse events. Conclusions: Our experience with linezolid suggests that it can be an alternative for the treatment of MRCoNS- and MRSA-related meningitis.